.Kaufmann, P., Pariser, A. R. & Austin, C. Coming from scientific revelation to treatments for rare diseasesu00e2 $" the view from the National Facility for Accelerating Translational Sciencesu00e2 $" Workplace of Rare Diseases Study. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T. A call to upper arms against ultra-rare health conditions. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Vockley, J. et cetera. The advancing role of medical geneticists in the time of genetics treatment: a seriousness to prepare. Genet. Medication. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide treatment for an unusual hereditary condition. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et cetera. A structure for customized splice-switching oligonucleotide treatment. Structure 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lima, W. F. et cetera. Human RNase H1 discriminates in between subtle variations in the framework of the heteroduplex substratum. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X.-H. Antisense modern technology: a review and prospectus. Nat. Rev. Medicine Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lee, J.-R. et al. Afresh anomalies in the electric motor domain of KIF1A reason intellectual disability, spastic paraparesis, axonal neuropathy, as well as cerebellar atrophy. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Boyle, L. et al. Genotype and also flaws in microtubule-based mobility correlate with medical severity in KIF1A-associated nerve disorder. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Motor protein KIF1A is actually necessary for hippocampal synaptogenesis as well as learning enhancement in a developed setting. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Guo, Y. et al. An uncommon KIF1A missense mutation boosts synaptic function as well as increases seizure task. Front. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kaur, S. et al. Growth of the phenotypic sphere of afresh missense versions in kinesin member of the family 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Canivez, G. L. & McGill, R. J. Factor construct of the Differential Capacity Scales-Second Version: exploratory and also hierarchical factor evaluations with the primary subtests. Psychol. Determine. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Epstein, A. et cetera. Material verification of the lifestyle inventoryu00e2 $" impairment. Childcare Wellness Dev. 45, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Lek, M. et cetera. Study of protein-coding hereditary variation in 60,706 humans. Attributes 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medicine Products for Significantly Incapacitating or Life-Threatening Health Conditions: Medical Referrals (US Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Articles for Tailored Antisense Oligonucleotide Drug Products: Management and Procedural Referrals Assistance for Sponsor-Investigators (US Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Drug Application Submissions for Tailored Antisense Oligonucleotide Medication Products for Severely Incapacitating or Lethal Health Conditions: Chemistry, Manufacturing, as well as Controls Recommendations, Assistance for Sponsor-Investigators (US Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Testing of Individualized Antisense Oligonucleotide Medication Products for Badly Devastating or Severe Ailments Assistance for Sponsor-Investigators (US Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.